Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 6
2012 3
2013 3
2014 6
2015 3
2016 2
2017 1
2018 4
2019 7
2020 7
2021 4
2022 6
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Advances in lung cancer.
Pacheco JM, Dimou A, Bunn PA. Pacheco JM, et al. Among authors: dimou a. Oncotarget. 2017 Sep 13;8(45):78247-78248. doi: 10.18632/oncotarget.20854. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108218 Free PMC article. No abstract available.
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. Nagasaka M, et al. Among authors: dimou a. Future Oncol. 2023 Jan;19(2):123-135. doi: 10.2217/fon-2022-1059. Epub 2023 Mar 6. Future Oncol. 2023. PMID: 36877099 Free article.
New Developments in Neoadjuvant Therapy for Lung Cancer.
Bunn PA Jr, Schenk E, Pacheco J, Dimou A. Bunn PA Jr, et al. Among authors: dimou a. Oncology (Williston Park). 2019 Mar 13;33(3):101-6, 109. Oncology (Williston Park). 2019. PMID: 30866032 Free article. Review.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: dimou a. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
60 results